January 19, 2006 11:01 ET

Studies Show Nymox's AlzheimAlert™ Test Useful in Earliest Stage of Alzheimer's

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Jan 19, 2006) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that recent studies have shown that the Company's AlzheimAlert™ test can be useful in the clinical evaluation of the earliest stages of Alzheimer's disease (AD). AlzheimAlert™ is Nymox's proprietary test which measures urinary levels of neural thread protein (NTP), which is elevated in AD. As part of a broad range of studies investigating the utility of the AlzheimAlert™ technology, individuals with mild cognitive impairment (MCI) have been found to have significant findings in their AlzheimAlert™ test results. MCI is believed to be the earlier recognizable stage of the evolution of AD.

Results from the independently undertaken MCI studies of AlzheimAlert™ will be presented at national and international meetings this year, and published in the medical literature in due course.

There is an extensive scientific and medical literature on the brain protein (neural thread protein or NTP) detected by the Company's Alzheimer test and on its usefulness as an aid to the diagnosis of Alzheimer's disease. Publications include, for example, Journal of Alzheimer's Disease (2004; 6(3): 231-42) and (2001; 3: 345-353); Cellular and Molecular Life Sciences (2003; 60: 2679-91) and (2001; 58: 844-849); Alzheimer's Reports (2002; 1: 1-6); Neurology & Clinical Neurophysiology (2002; 1: 2-7); Frontiers in Bioscience (2002; 7:d989-96); Journal of Neuropathology and Experimental Neurology (2001; 60: 195-207) and (1996; 55: 1038-1050); Neurology (2000; 55: 1068) and (2000; 54: 1498-1504); Alzheimer's Reports (2001; 4: 61-65), (2000; 3: 177-184) and (1999; 2: 327-332); Journal of Clinical Laboratory Analysis (1998; 12: 285-288) and (1998; 12: 223-226); Journal of Contemporary Neurology (1998; 4A: 2-6); and Journal of Clinical Investigation (1997; 100: 3093-3104).

There are an estimated 4.5 million people with Alzheimer's disease in the United States alone; by 2050 this number is projected to increase almost three times to 13.2 million. Worldwide estimates of the current number of people with Alzheimer's disease range from 15 to 20 million. The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone are estimated at $100 billion. The human toll on patients, families and caregivers is incalculable.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX